(2S,4S)-4-(4-(2-acetamidothiazolo[5,4-b]pyridin-5-yl)-1H-1,2,3-triazol-1-yl)-N-(4-bromophenyl)pyrrolidine-2-carboxamide

ID: ALA5183302

Chembl Id: CHEMBL5183302

PubChem CID: 168282105

Max Phase: Preclinical

Molecular Formula: C21H19BrN8O2S

Molecular Weight: 527.41

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)Nc1nc2ccc(-c3cn([C@@H]4CN[C@H](C(=O)Nc5ccc(Br)cc5)C4)nn3)nc2s1

Standard InChI:  InChI=1S/C21H19BrN8O2S/c1-11(31)24-21-27-16-7-6-15(26-20(16)33-21)18-10-30(29-28-18)14-8-17(23-9-14)19(32)25-13-4-2-12(22)3-5-13/h2-7,10,14,17,23H,8-9H2,1H3,(H,25,32)(H,24,27,31)/t14-,17-/m0/s1

Standard InChI Key:  JJFYUQKAJYRNHL-YOEHRIQHSA-N

Alternative Forms

  1. Parent:

    ALA5183302

    ---

Associated Targets(Human)

ABL1 Tclin Bcr/Abl fusion protein (1667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562/Adr (229 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

BaF3 (4657 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 527.41Molecular Weight (Monoisotopic): 526.0535AlogP: 3.21#Rotatable Bonds: 5
Polar Surface Area: 126.72Molecular Species: BASEHBA: 9HBD: 3
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 7.95CX Basic pKa: 9.06CX LogP: 2.03CX LogD: 1.52
Aromatic Rings: 4Heavy Atoms: 33QED Weighted: 0.36Np Likeness Score: -1.84

References

1. Pan X, Liu N, Liu Y, Zhang Q, Wang K, Liu X, Zhang J..  (2022)  Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.,  238  [PMID:35561654] [10.1016/j.ejmech.2022.114425]

Source